Abstract
Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.
Original language | English |
---|---|
Pages (from-to) | 59-68 |
Number of pages | 10 |
Journal | Therapeutic Advances in Urology |
Volume | 7 |
Issue number | 2 |
DOIs | |
Publication status | Published - Apr 27 2015 |
Keywords
- predictive factors
- renal cell carcinoma
- sites of metastases
- sorafenib
- sunitinib
ASJC Scopus subject areas
- Urology